Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Weekly Carboplatin in TNBC
NCT04083963Phase 2Active, not recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Aug 2019
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin in triple-negative breast cancer (TNBC), sponsored by University of Illinois Chicago. Started Aug 2019; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04083963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083963.